Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Jefferies Healthcare Conference London 2023
28 slides from Nykode Therapeutics Asa's conference presentation, Nov 16, 2023
Slide 1: Jefferies Healthcare Conference
Jefferies Healthcare Conference London, November 16, 2023
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Global leader in antigen presenting cell (APC)-targeted immunotherapy technology
Global leader in antigen presenting cell (APC)-targeted immunotherapy technology NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$560M1) Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases Str
Slide 4: Top-tier collaborations for cancer and infectious disease vaccines valued at more than $1.64bn plus royalties
Top-tier collaborations for cancer and infectious disease vaccines valued at more than $1.64bn plus royalties Partner Collaboration Terms Clinical Development $925M~ Regeneron to develop and potentially Multi-target license and $30M upfront commercialize products collaboration agreement to $20M
Slide 5: Rich and diversified pipeline
Rich and diversified pipeline Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 Initiate trial HPV16+ cervical cancer (Q4 2023) 2 Dose level VB10.16 HPV16+ head and neck cancer recommendation (H2 2024) 2 Off-the-shelf HPV16+ locally advanced Protocol in cervica
Slide 6: Vaccibody vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells
Vaccibody vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells MECHANISM OF ACTION – T CELL INDUCTION Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 6
Slide 7: VB10.16 in HPV16+ cancers
VB10.16 in HPV16+ cancers Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 7
Slide 8: VB10.16: Therapeutic vaccine candidate for HPV16+ cancers
VB10.16: Therapeutic vaccine candidate for HPV16+ cancers Targeting unit Off-the-shelf therapeutic cancer DNA vaccine CCL3L1 against HPV16 induced malignancies HPV16 is the most prevalent oncogenic HPV strain VB10.16 Targeting the cancer-specific full-length HPV16 E7 and E6 Off-the-shelf vaccine
Slide 9: HPV+ cancer incidence is expected to increase despite prophylactic HPV vaccination
HPV+ cancer incidence is expected to increase despite prophylactic HPV vaccination HPV16+ cancers are a significant unmet need HPV+ cervical cancer HPV-related cancer incidence is expected to grow • 4th most common cancer in women worldwide HPV+ cervical cancer HPV+ HNSCC • 4th leading cause of canc
Slide 10: VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in 2L r/m cervical cancer
VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in 2L r/m cervical cancer CPI Monotherapy in r/m CC VB10.16 plus Atezolizumab in Pembrolizumab in Cemiplimab in Tisotumab vedotin Endpoint atezolizumab PD-L1+††† PD-L1+** PD-L1+ †† (PD-L1 agnostic) ‡ ‡ in PD-L1+ Skyscraper
Slide 11: Maximizing shareholder value by diversifying offerings and broadening therapeutic scope
Maximizing shareholder value by diversifying offerings and broadening therapeutic scope Building a cancer vaccine franchise following strong clinical validation Validation Today Future Opportunities Adjuvant Settings Move earlier to expand patient population and Indication Expansions explore long-te
Slide 12: Creating a portfolio of targeted vaccines for HPV16+ cancers
Creating a portfolio of targeted vaccines for HPV16+ cancers VB10.16 portfolio C-02 C-03 C-04 C-05 r/m head and neck r/m Cervical Cancer, ≥2L r/m Cervical Cancer, Locally Advanced Indication cancer (HNSCC), PD-L1+, 2L Cervical Cancer (LACC) PD-L1+, 1L Up to 9 mg in 3 mg in combination with combinati
Slide 13: VB10.NEO Full individualized cancer vaccine
VB10.NEO Full individualized cancer vaccine Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 13
Slide 14: VB10.NEO: Nykode's individualized cancer vaccine
VB10.NEO: Nykode’s individualized cancer vaccine Broad clinical experience 2 clinical trials in more than 10 cancer indications in recurrent metastatic setting Promising immunogenicity data VB10.NEO Broad and durable T cell responses in the Fully individualized vaccine against the clinic multipl
Slide 15: VB10.NEO programs
VB10.NEO programs Safety clearance of 9 mg dose with no safety concerns and no dose limiting toxicities observed N-01 N-02 r/m Melanoma, non-small cell lung cancer (NSCLC), clear renal cell carcinoma, urothelial Indication r/m cancer, covering more than ten indications cancer or squamous cell carcin
Slide 16: Broad and durable neoantigen-specific T cell responses
Broad and durable neoantigen-specific T cell responses DURABLE NEO-AG SPECIFIC T CELL BROAD T CELL RESPONSES IN ALL PATIENTS RESPONSES, ALSO POST VACCINATION Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 16
Slide 17: Autoimmunity and further platform potential
Autoimmunity and further platform potential Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 17
Slide 18: Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with DNA plasmid vaccine CD4+ Treg Tol APC CD4+ Treg Tol APC Effector T Effector T cell cell Cells encod
Slide 19: Recombinant Vaccibodies targeting tolerogenic DCs prevents serious disease in a MS-like mouse disease model
Recombinant Vaccibodies targeting tolerogenic DCs prevents serious disease in a MS-like mouse disease model Daily clinical scores Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) day -7 day -3 day 0 day 29 where the immune system attacks nerve cells in the brain a
Slide 20: Low dose prevent MS disease symptoms, with a dose-dependent decrease in disease associated cytokines
Low dose prevent MS disease symptoms, with a dose-dependent decrease in disease associated cytokines differentiated from Ag alone EAE MODEL Daily clinical scores day -7 day -3 day 0 day 15 Immune parameter read-out at day 15 (at peak of disease) Disease Termination and induction immune analyses MOG(
Slide 21: Disease prevention in the EAE model can also be achieved by targeting an alternative target
Disease prevention in the EAE model can also be achieved by targeting an alternative target on tolerizing APCs EAE MODEL Paralysis VB vaccine TV004 5 ✱✱✱ Untreated 80 35 µg VB vaccine TV004 Targeting unit 1 4 Target 1 60 EAE score AUC (5-29) 3 40 2 20 EAE 1 0 antigen ed ne 0 e at c ci r va Tol 6 8 1
Slide 22: DNA vaccination with Vaccibody targeting tolerogenic APCs prevents type 1 diabetes in a spontaneous mice model
DNA vaccination with Vaccibody targeting tolerogenic APCs prevents type 1 diabetes in a spontaneous mice model Type 1 diabetes is an autoimmune disease where the immune system attacks insulin producing cells in the pancreas Day 0 day 7 day 14 The Non-Obese Diabetic (NOD) model is a mouse diabetes mo
Slide 23: Nykode's APC targeting leads to faster, stronger and broader T cell responses
NYKODE’S TECH IMPROVES Nykode’s APC targeting leads to faster, MRNA VACCINES stronger and broader T cell responses • Preclinical data shows that using APC targeted neoepitope vaccines with mRNA-LNP, whether delivered via DNA or mRNA, leads to stronger and broader T cell responses. • Nearly doubled n
Slide 24: Financial overview & outlook
Financial overview & outlook Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential 24
Slide 25: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Cash position of $159m end Q3 2023 Financially well positioned to execute the Company’s strategy over the next years Nykode continues to explore a potential listing on the Nasdaq Global Market in the United States Nykode Therapeutics | Jefferi
Slide 26: Subsequent events
Subsequent events Private placement Tax matter Norwegian Tax Authorities (NTA) reiterated Successfully raised $45m in private placement their position that upfront payments received Aim to broaden the existing shareholder base under a license agreement entered into in with international invest
Slide 27: Upcoming milestones
Upcoming milestones Q4 VB10.16 Initiate potentially registrational VB-C-04 trial in the U.S. in patients with 2023 Cervical Cancer recurrent/metastatic disease and PD-L1 positive tumors Q4 Undisclosed Nomination of an additional oncology development candidate for a new internal 2023 Oncology oncolog
Slide 28: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Jefferies Healthcare Conference | Non-confidential
Nykode Therapeutics — Jefferies Healthcare Conference London 2023 on 6ix